Microsatellite Stable Colorectal Cancer Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Microsatellite Stable Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Microsatellite Stable Colorectal Cancer pipeline landscape. It covers the Microsatellite Stable Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Microsatellite Stable Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Microsatellite Stable Colorectal Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Microsatellite Stable Colorectal Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Microsatellite Stable Colorectal Cancer Pipeline Report
• In May 2025, BeiGene announced a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
• In May 2025, CytoDyn Inc. conducted a study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study.
• In May 2025, Agenus Inc. organized a Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
• DelveInsight's Microsatellite Stable Colorectal Cancer Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Microsatellite Stable Colorectal Cancer treatment.
• The leading Microsatellite Stable Colorectal Cancer Companies such as GI Innovation Inc., Bristol-Myers Squibb, NeoImmuneTech, Parabilis Medicines Inc., Agenus Inc., NextCure Inc., Merck Sharp & Dohme LLC and others.
• Promising Microsatellite Stable Colorectal Cancer Pipeline Therapies such as Evorpacept (ALX148), Cetuximab, Pembrolizumab, Nivolumab, Relatlimab, Niraparib, eFT508, Avelumab, Vicriviroc and others.

Stay ahead with the most recent pipeline outlook for Microsatellite Stable Colorectal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Microsatellite Stable Colorectal Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Microsatellite Stable Colorectal Cancer Emerging Drugs Profile
• GRANITE: Gritstone Oncology
GRANITE, is a personalized neoantigen-based immunotherapy. It is being evaluated in the Phase 2 portion of a Phase 1/2 clinical study in combination with checkpoint inhibitors for patients with microsatellite stable colorectal cancer (MSS CRC) who have progressed on FOLFOX/FOLFIRI therapy and a second cohort for patients with gastro-esophageal cancer who have progressed on chemotherapy. GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS CRC.

• MK7123-034: Merck Sharp & Dohme Corp.
The study is currently in phase II to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

The Microsatellite Stable Colorectal Cancer Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Microsatellite Stable Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microsatellite Stable Colorectal Cancer Treatment.
• Microsatellite Stable Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Microsatellite Stable Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Microsatellite Stable Colorectal Cancer market

Explore groundbreaking therapies and clinical trials in the Microsatellite Stable Colorectal Cancer Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Microsatellite Stable Colorectal Cancer Drugs- https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Microsatellite Stable Colorectal Cancer Companies
GI Innovation Inc., Bristol-Myers Squibb, NeoImmuneTech, Parabilis Medicines Inc., Agenus Inc., NextCure Inc., Merck Sharp & Dohme LLC and others.

Microsatellite Stable Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Microsatellite Stable Colorectal Cancer Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Unveil the future of Microsatellite Stable Colorectal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Microsatellite Stable Colorectal Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Microsatellite Stable Colorectal Cancer Pipeline Report
• Coverage- Global
• Microsatellite Stable Colorectal Cancer Companies- GI Innovation Inc., Bristol-Myers Squibb, NeoImmuneTech, Parabilis Medicines Inc., Agenus Inc., NextCure Inc., Merck Sharp & Dohme LLC and others.
• Microsatellite Stable Colorectal Cancer Pipeline Therapies - Evorpacept (ALX148), Cetuximab, Pembrolizumab, Nivolumab, Relatlimab, Niraparib, eFT508, Avelumab, Vicriviroc and others.
• Microsatellite Stable Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Microsatellite Stable Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Microsatellite Stable Colorectal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Microsatellite Stable Colorectal Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Microsatellite Stable Colorectal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Microsatellite Stable Colorectal Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Microsatellite Stable Colorectal Cancer Collaboration Deals
9. Mid Stage Products (Phase III)
10. MK7123-034: Merck Sharp & Dohme Corp.
11. Drug profiles in the detailed report.....
12. Early Stage Products (Phase I/II)
13. GRANITE: Gritstone Oncology
14. Drug profiles in the detailed report.....
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report.....
17. Inactive Products
18. Microsatellite Stable Colorectal Cancer Key Companies
19. Microsatellite Stable Colorectal Cancer Key Products
20. Microsatellite Stable Colorectal Cancer- Unmet Needs
21. Microsatellite Stable Colorectal Cancer- Market Drivers and Barriers
22. Microsatellite Stable Colorectal Cancer- Future Perspectives and Conclusion
23. Microsatellite Stable Colorectal Cancer Analyst Views
24. Microsatellite Stable Colorectal Cancer Key Companies
25. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.